Persistence and efficacy of second generation CAR T Cell against the LeY Antigen in acute myeloid leukemia

Molecular Therapy

Volumn 21, Issue 11, 2013, Pages 2122-2129

  Ritchie, David S ^a,b   Neeson, Paul J ^a,b   Khot, Amit ^b   Peinert, Stefan ^b   Tai, Tsin ^b   Tainton, Kellie ^b   Chen, Karen ^b   Shin, Mandy ^b   Wall, Dominic M ^b,c   Hönemann, Dirk ^b   Gambell, Peter ^b   Westerman, David A ^b   Haurat, Javier ^b   Westwood, Jennifer A ^a,b   Scott, Andrew M ^c   Kravets, Lucy ^b   Dickinson, Michael ^b   Trapani, Joseph A ^a,b   Smyth, Mark J ^a,b   Darcy, Phillip K ^a,b   Kershaw, Michael H ^a,b   Prince, H Miles ^a,b   more..

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; FLUDARABINE; GAMMA INTERFERON; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; INDIUM 111; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; TUMOR NECROSIS FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE TRANSFER; ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BONE MARROW; CELL MIGRATION; CELL TRACKING; CHIMERIC ANTIGEN RECEPTOR T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; IN VIVO STUDY; LEUKEMIA RELAPSE; LEY GENE; LYMPHOCYTIC INFILTRATION; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; RASH; REMISSION; SAFETY; T LYMPHOCYTE; TRANSGENE;

AGED; BONE MARROW; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA, MYELOID, ACUTE; LEWIS BLOOD-GROUP SYSTEM; MALE; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL; REMISSION INDUCTION; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; VIDARABINE;

EID: 84887419384     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.154     Document Type: Article

References (39)

1. Gupta, V, Tallman, MS and Weisdorf, DJ (2011). Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood 117: 2307-2318.
2. Kershaw, MH, Westwood, JA, Parker, LL, Wang, G, Eshhar, Z, Mavroukakis, SA et al. (2006). A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12(20 Pt 1): 6106-6115.
3. Wen, YJ, Barlogie, B and Yi, Q (2001). Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood 97: 1750-1755.
4. Wen, YJ, Min, R, Tricot, G, Barlogie, B and Yi, Q (2002). Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood 99: 3280-3285.
5. Parker, LL, Do, MT, Westwood, JA, Wunderlich, JR, Dudley, ME, Rosenberg, SA et al. (2000). Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Hum Gene Ther 11: 2377-2387.
6. Cooper, LJ, Ausubel, L, Gutierrez, M, Stephan, S, Shakeley, R, Olivares, S et al. (2006). Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma. Cytotherapy 8: 105-117.
7. Lamers, CH, Willemsen, RA, Luider, BA, Debets, R and Bolhuis, RL (2002). Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer. Cancer Gene Ther 9: 613-623.
8. Stancovski, I, Schindler, DG, Waks, T, Yarden, Y, Sela, M and Eshhar, Z (1993). Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol 151: 6577-6582.
9. Hwu, P, Shafer, GE, Treisman, J, Schindler, DG, Gross, G, Cowherd, R et al. (1993). Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med 178: 361-366.
10. Sadelain, M, Rivière, I and Brentjens, R (2003). Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 3: 35-45.
11. Kershaw, MH, Westwood, JA and Hwu, P (2002). Dual-specific T cells combine proliferation and antitumor activity. Nat Biotechnol 20: 1221-1227.
12. Moritz, D, Wels, W, Mattern, J and Groner, B (1994). Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA 91: 4318-4322.
13. Eshhar, Z, Waks, T, Gross, G and Schindler, DG (1993). Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90: 720-724.
14. Haynes, NM, Trapani, JA, Teng, MW, Jackson, JT, Cerruti, L, Jane, SM et al. (2002). Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100: 3155-3163.
15. Maher, J, Brentjens, RJ, Gunset, G, Rivière, I and Sadelain, M (2002). Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 20: 70-75.
16. Pulè, MA, Straathof, KC, Dotti, G, Heslop, HE, Rooney, CM and Brenner, MK (2005). A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 12: 933-941.
17. Kochenderfer, JN, Dudley, ME, Feldman, SA, Wilson, WH, Spaner, DE, Maric, I et al. (2012). B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119: 2709-2720.
18. Porter, DL, Levine, BL, Kalos, M, Bagg, A and June, CH (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733.
19. Yin, BW, Finstad, CL, Kitamura, K, Federici, MG, Welshinger, M, Kudryashov, V et al. (1996). Serological and immunochemical analysis of Lewis y (Ley) blood group antigen expression in epithelial ovarian cancer. Int J Cancer 65: 406-412.
20. Zhang, S, Zhang, HS, Cordon-Cardo, C, Reuter, VE, Singhal, AK, Lloyd, KO et al. (1997). Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer 73: 50-56.
21. Sakamoto, J, Furukawa, K, Cordon-Cardo, C, Yin, BW, Rettig, WJ, Oettgen, HF et al. (1986). Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines. Cancer Res 46: 1553-1561.
22. Kobayashi, K, Sakamoto, J, Kito, T, Yamamura, Y, Koshikawa, T, Fujita, M et al. (1993). Lewis blood group-related antigen expression in normal gastric epithelium, intestinal metaplasia, gastric adenoma, and gastric carcinoma. Am J Gastroenterol 88: 919-924.
23. Miyake, M, Taki, T, Hitomi, S and Hakomori, S (1992). Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. N Engl J Med 327: 14-18.
24. Westwood, JA, Smyth, MJ, Teng, MW, Moeller, M, Trapani, JA, Scott, AM et al. (2005). Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci USA 102: 19051-19056.
25. Neeson, P, Shin, A, Tainton, KM, Guru, P, Prince, HM, Harrison, SJ et al. (2010). Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype. Gene Ther 17: 1105-1116.
26. Peinert, S, Prince, HM, Guru, PM, Kershaw, MH, Smyth, MJ, Trapani, JA et al. (2010). Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Ther 17: 678-686.
27. Brentjens, RJ, Rivière, I, Park, JH, Davila, ML, Wang, X, Stefanski, J et al. (2011). Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118: 4817-4828.
28. Till, BG, Jensen, MC, Wang, J, Qian, X, Gopal, AK, Maloney, DG et al. (2012). CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119: 3940-3950.
29. Lee, DW, Barrett, DM, Mackall, C, Orentas, R and Grupp, SA (2012). The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res 18: 2780-2790.
30. Kalos, M, Levine, BL, Porter, DL, Katz, S, Grupp, SA, Bagg, A et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3: 95ra73.
31. Morgan, RA, Yang, JC, Kitano, M, Dudley, ME, Laurencot, CM, and Rosenberg, SA (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18: 843-851.
32. Burns, WR, Zheng, Z, Rosenberg, SA and Morgan, RA (2009). Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. Blood 114: 2888-2899.
33. Zhou, Q, Munger, ME, Veenstra, RG, Weigel, BJ, Hirashima, M, Munn, DH et al. (2011). Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 117: 4501-4510.
34. Norde, WJ, Hobo, W, van der Voort, R and Dolstra, H (2012). Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. Blood 120: 728-736.
35. Phan, GQ, Yang, JC, Sherry, RM, Hwu, P, Topalian, SL, Schwartzentruber, DJ et al. (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100: 8372-8377.
36. Saenger, YM and Wolchok, JD (2008). The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun 8: 1.
37. Small, EJ, Tchekmedyian, NS, Rini, BI, Fong, L, Lowy, I and Allison, JP (2007). A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13: 1810-1815.
38. Topalian, SL, Hodi, FS, Brahmer, JR, Gettinger, SN, Smith, DC, McDermott, DF et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454.
39. Prince, HM, Wall, DM, Ritchie, D, Honemann, D, Harrrison, S, Quach, H et al. (2008). In vivo tracking of dendritic cells in patients with multiple myeloma. J Immunother 31: 166-179.